RBC Downgrades Amrize After A Rare Q2 Miss
RBC downgraded Amrize after a rare Q2 miss and reduced guidance, citing a timing mismatch between input-cost increases and the full pass-through of surcharges and price hikes. RBC cut 2026-2028 EBITDA estimates by 4%, 6%, and 7% and EPS by 12%, 14%, and 15%, lowering its stock rating to underperform and price target to $48 from $60.
How this was made
The 30-second read
Why it matters
RBC interprets the guidance mismatch as lasting longer than hoped, lowering multi-year EBITDA and EPS estimates and trimming its price target, which can trigger multiple compression and further estimate revisions.
Market read
With RBC’s $48 target close to the current ~$46.49 price, the market may be sensitive to additional analyst downgrades or forecast trims.
What to watch
The article does not quantify backlog, demand trends, or margin recovery timing, which could limit how far revisions actually go.
Background
The piece attributes Amrize’s profit squeeze to input-cost increases arriving before surcharges and price hikes fully flow through, leading to a guidance cut.
Ticker impact
RBC downgraded Amrize to underperform and cut its 2026-2028 EBITDA and EPS estimates after a rare Q2 miss and guidance cut.
Near-term pressure likely if other analysts follow with estimate cuts; upside requires evidence the profit squeeze is temporary.
The article cites explicit multi-year forecast reductions and a tighter valuation cushion versus RBC’s $48 target versus the $46.49 share price.
Market effects
Could contribute to broader “earnings revisions” risk for construction/industrial names if profit-mismatch dynamics appear persistent.
No specific regional spillover mentioned.
No global macro or cross-border catalyst cited.
Counterpoint
If the profit squeeze is mainly timing-related and surcharges/price hikes fully catch up soon, the multi-year cuts may be overly pessimistic.
Key entities
- analyst_firmRBC
Issued the downgrade to underperform and cut longer-term forecasts and the price target for Amrize.
- companyAmrize
Subject of the rare Q2 miss, guidance cut, and RBC’s subsequent multi-year estimate reductions.
